Anaptys Announces Participation in Upcoming Investor Conferences

November 10, 2026

SAN DIEGO, Nov. 10, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for *Jemperli* with Tesaro, a GSK company, and *Quimilza* (imsidolimab) with Vanda, today announced that members of its executive team are scheduled to participate in multiple upcoming investor conferences:

UBS Global Biopharma Conference 2026, London

- Format – Fireside chat
- Date and Time – Tuesday, November 17, 2026 at 4:40pm GMT / 11:40am ET
- Participant – Daniel Faga, president and chief executive officer

Piper Sandler 38th Annual Healthcare Conference, New York

- Format – Fireside chat and one-on-one investor meetings
- Date and Time – Wednesday, December 2, 2026 at 8:00am ET
- Participant – Chris Murphy, chief financial officer

9th Annual Evercore Healthcare Conference, Miami

- Format – Fireside chat
- Date and Time – Wednesday, December 2, 2026 at 10:50am ET
- Participant – Daniel Faga, president and chief executive officer

Live webcasts of the fireside chats will be available on the investor section of the Anaptys website at https://ir.anaptysbio.com/presentations-and-events. Replays of the webcasts will be available for at least 30 days following the events.

About Anaptys

Anaptys manages the financial collaborations for *Jemperli* with GSK and *Quimilza* with Vanda, with a focus on protecting and returning the value of its royalties to shareholders. To learn more, visit www.AnaptysBio.com or follow us on LinkedIn.

Contact:
Chris Murphy
Chief Financial Officer
investors@anaptysbio.com